论文部分内容阅读
为探讨培垛普利与吲哒帕胺单独治疗和联合治疗对高血压病患者血浆氧化型低密度脂蛋白水平的影响 ,将 85例高血压病患者随机分为三组 ,即培垛普利组 (n =30 ,每天 4mg) ,吲哒帕胺组 (n =30 ,每天 2 .5mg) ,培垛普利和吲哒帕胺联合治疗组 (n =2 5 ,培垛普利每天 4mg;吲哒帕胺每天 2 .5mg) ,疗程 8周 ,观察治疗前后血清脂质及血浆氧化型低密度脂蛋白水平的变化。结果发现 ,培垛普利、吲哒帕胺及其联合治疗均能显著降低高血压患者血压及血浆氧化型低密度脂蛋白水平 ,但血浆氧化型低密度脂蛋白降低幅度在联合治疗组较培垛普利或吲哒帕胺单独治疗组明显增高 ,而培垛普利组和吲哒帕胺组比较无显著性差异。三组治疗后血浆氧化型低密度脂蛋白下降幅度与血压下降幅度无显著相关。结果提示 ,培垛普利和吲哒帕胺单独治疗或联合应用均能抑制高血压患者低密度脂蛋白在体内的氧化修饰过程 ,而联合治疗有一定协同作用
In order to investigate the effect of propofol and indapamide monotherapy and combination therapy on the plasma level of oxidized low density lipoprotein in hypertensive patients, 85 patients with essential hypertension were randomly divided into three groups: Group (n = 30, 4 mg daily), indapamide group (n = 30, 2.5 mg daily), combination therapy with pentobarbital and indapamide (n = 25, Indapamide 2.5mg daily) for 8 weeks. Changes of serum lipids and plasma oxidized low density lipoprotein levels before and after treatment were observed. The results showed that both pulsatile, indapamide and their combination therapy can significantly reduce the blood pressure and plasma levels of oxidized low-density lipoprotein in patients with hypertension, but the decrease of plasma oxidized low-density lipoprotein in the combined treatment group than in the training group There was no significant difference between streptozapril and indapamide in the monotherapy group and no significant difference between the peptidic and indapamide groups. Three groups of plasma oxidized low-density lipoprotein after treatment decreased with no significant correlation between blood pressure decline. The results suggest that either pulblendin and indapamide alone or in combination can inhibit the oxidative modification of LDL in patients with hypertension, and the combination therapy has some synergistic effects